[House Report 118-622]
[From the U.S. Government Publishing Office]


118th Congress    }                                      {      Report
                        HOUSE OF REPRESENTATIVES
 2d Session       }                                      {     118-622

======================================================================



 
   WOMEN AND LUNG CANCER RESEARCH AND PREVENTIVE SERVICES ACT OF 2024

                                _______
                                

 July 30, 2024.--Committed to the Committee of the Whole House on the 
              State of the Union and ordered to be printed

                                _______
                                

      Mrs. Rodgers of Washington, from the Committee on Energy and
                   Commerce, submitted the following

                              R E P O R T

                        [To accompany H.R. 4534]

    The Committee on Energy and Commerce, to whom was referred 
the bill (H.R. 4534) to require a review of women and lung 
cancer, and for other purposes, having considered the same, 
reports favorably thereon with an amendment and recommends that 
the bill as amended do pass.

                                CONTENTS

                                                                   Page
Purpose and Summary..............................................     2
Background and Need for Legislation..............................     2
Committee Action.................................................     3
Committee Votes..................................................     3
Oversight Findings and Recommendations...........................     5
New Budget Authority, Entitlement Authority, and Tax Expenditures     5
Congressional Budget Office Estimate.............................     5
Federal Mandates Statement.......................................     5
Statement of General Performance Goals and Objectives............     5
Duplication of Federal Programs..................................     5
Related Committee and Subcommittee Hearings......................     5
Committee Cost Estimate..........................................     6
Earmark, Limited Tax Benefits, and Limited Tariff Benefits.......     6
Advisory Committee Statement.....................................     6
Applicability to Legislative Branch..............................     6
Section-by-Section Analysis of the Legislation...................     6
Changes in Existing Law Made by the Bill, as Reported............     7

    The amendment is as follows:
  Strike all after the enacting clause and insert the 
following:

SECTION 1. SHORT TITLE.

  This Act may be cited as the ``Women and Lung Cancer Research and 
Preventive Services Act of 2024''.

SEC. 2. INTERAGENCY REVIEW TO EVALUATE AND IDENTIFY OPPORTUNITIES FOR 
                    THE ACCELERATION OF RESEARCH ON LUNG CANCER IN 
                    WOMEN AND UNDERSERVED POPULATIONS, GREATER ACCESS 
                    TO PREVENTIVE SERVICES, AND STRATEGIC PUBLIC 
                    AWARENESS AND EDUCATION CAMPAIGNS.

  (a) In General.--The Secretary of Health and Human Services, in 
consultation with the Secretary of Defense and Secretary of Veterans 
Affairs, shall conduct an interagency review to evaluate the status of, 
and identify opportunities related to--
          (1) research on lung cancer in women;
          (2) research on lung cancer in underserved populations that 
        meet the eligibility criteria for lung cancer screening as 
        recommended by the United States Preventive Services Task 
        Force;
          (3) access to lung cancer preventive services; and
          (4) strategic public awareness and education campaigns on 
        lung cancer.
  (b) Content.--The review and recommendations under subsection (a) 
shall include--
          (1) a review and comprehensive report on the outcomes of 
        previous research, the status of existing research activities, 
        and knowledge gaps related to lung cancer in women and 
        underserved populations in all agencies of the Federal 
        Government;
          (2) opportunities for collaborative, interagency, 
        multidisciplinary, and innovative research, that would--
                  (A) encourage innovative approaches to eliminate 
                knowledge gaps in research on lung cancer in women;
                  (B) evaluate environmental and genomic factors that 
                may be related to the etiology of lung cancer in women; 
                and
                  (C) foster advances in imaging technology and 
                techniques to improve risk assessment, diagnosis, 
                treatment, and the simultaneous utilization of other 
                preventive services and activities;
          (3) opportunities regarding the development of a national 
        lung cancer screening strategy to expand access to such 
        screenings, particularly among women and underserved 
        populations; and
          (4) opportunities regarding the development of a national 
        public education and awareness campaign on--
                  (A) lung cancer in women and underserved populations; 
                and
                  (B) the importance of early detection of lung cancer.
  (c) Report.--Not later than two years after the date of the enactment 
of this Act, the Secretary of Health and Human Services shall submit to 
Congress a report on the review conducted under subsection (a).

                          PURPOSE AND SUMMARY

    H.R. 4534 requires The Department of Health and Human 
Services (HHS) to conduct an interagency review on the status 
of, and identify research related to, women and underserved 
populations with lung cancer. The review would include 
assessments of current research and access to prevention 
services, the availability of research opportunities regarding 
prevention, detection, and treatment, and recommendations for 
national public education and screening strategies.

                  BACKGROUND AND NEED FOR LEGISLATION

    Lung cancer is the third most common cancer in the United 
States.\1\ Worldwide, over 600,000 women die of lung cancer 
each year.\2\ About 10 to 20 percent of lung cancers, or 20,000 
to 40,000 lung cancers each year, happen in people who never 
smoked or smoked fewer than 100 cigarettes in their 
lifetime.\3\ A better understanding of additional risk factors 
beyond smoking cigarettes is needed for more effective 
screening, diagnosis, and treatment.
---------------------------------------------------------------------------
    \1\``Lung Cancer Statistics,'' U.S. Centers for Disease Control and 
Prevention, June 13, 2024, https://www.cdc.gov/lung-cancer/statistics/
?CDC_AAref_Val=https://www.cdc.gov/cancer/lung/statistics/index.htm.
    \2\``Women and Lung Cancer,'' Lung Cancer Research Foundation, 
https://www.lungcancer
researchfoundation.org/for-patients/women-and-lc/.
    \3\``Lung Cancer Among People Who Never Smoked,'' U.S. Centers for 
Disease Control and Prevention, December 4, 2023, https://www.cdc.gov/
lung-cancer/nonsmokers/index.html#::text=
cancer%2C%20and%20asbestos.-
,In%20the%20United%20States%2C%20about%2010%25%20to%
2020%25%20of,2%2C900%20of%20these%20lung%20cancers.
---------------------------------------------------------------------------
    H.R. 4534 would review and assess current research on lung 
cancer in women and certain underserved populations, as well as 
evaluate current relevant opportunities related to education 
and access to prevention, detection, and treatment services.

                            COMMITTEE ACTION

    On February 14, 2024, the Subcommittee on Health held a 
hearing on H.R. 4534. The title of the hearing was 
``Legislative Proposals to Support Patients and Caregivers.'' 
The Subcommittee received testimony from:
           Andy Shih, PhD, Chief Science Officer, 
        Autism Speaks;
           Corey Feist, JD, MBA, Co-Founder and CEO, 
        Dr. Lorna Breen Heroes' Foundation;
           Joanne Pike, DrPH, President and CEO, 
        Alzheimer's Association;
           Gordon Tomaselli, MD, Former President, 
        American Heart Association; Marilyn and Stanley M. Katz 
        Dean, Emeritus and Professor of Medicine, Albert 
        Einstein College of Medicine; Adjunct Professor of 
        Medicine, Johns Hopkins University School of Medicine;
           Michelle Whitten, President, CEO, and Co-
        Founder, Global Down Syndrome Foundation;
           Randy Strozyk, President, American Ambulance 
        Association; and,
           Christina Annunziata, MD, PhD, Senior Vice 
        President of Extramural Discovery Science, American 
        Cancer Society.
    On May 16, 2024, the Subcommittee on Health met in open 
markup session and forwarded H.R. 4534, as amended, to the full 
Committee by a record vote of 21 yeas to 0 nays.
    On June 12, 2024, the full Committee on Energy and Commerce 
met in open markup session and ordered H.R. 4534, as amended, 
favorably reported to the House by a record vote of 44 yeas and 
0 nays.

                            COMMITTEE VOTES

    Clause 3(b) of rule XIII requires the Committee to list the 
record votes on the motion to report legislation and amendments 
thereto. The following reflects the record votes taken during 
the Committee consideration:

    [GRAPHIC(S) NOT AVAILABLE IN TIFF FORMAT]

                 OVERSIGHT FINDINGS AND RECOMMENDATIONS

    Pursuant to clause 2(b)(1) of rule X and clause 3(c)(1) of 
rule XIII, the Committee held a hearing and made findings that 
are reflected in this report.

   NEW BUDGET AUTHORITY, ENTITLEMENT AUTHORITY, AND TAX EXPENDITURES

    Pursuant to clause 3(c)(2) of rule XIII, the Committee 
finds that H.R. 4534 would result in no new or increased budget 
authority, entitlement authority, or tax expenditures or 
revenues.

                  CONGRESSIONAL BUDGET OFFICE ESTIMATE

    Pursuant to clause 3(c)(3) of rule XIII, at the time this 
report was filed, the cost estimate prepared by the Director of 
the Congressional Budget Office pursuant to section 402 of the 
Congressional Budget Act of 1974 was not available.

                       FEDERAL MANDATES STATEMENT

    The Committee adopts as its own the estimate of Federal 
mandates prepared by the Director of the Congressional Budget 
Office pursuant to section 423 of the Unfunded Mandates Reform 
Act.

         STATEMENT OF GENERAL PERFORMANCE GOALS AND OBJECTIVES

    Pursuant to clause 3(c)(4) of rule XIII, the general 
performance goal or objective of this legislation is to review, 
evaluate the status of, and identify research and educational 
opportunities related to lung cancer in women and certain 
underserved populations.

                    DUPLICATION OF FEDERAL PROGRAMS

    Pursuant to clause 3(c)(5) of rule XIII, no provision of 
H.R. 4534 is known to be duplicative of another Federal 
program, including any program that was included in a report to 
Congress pursuant to section 21 of Public Law 111-139 or the 
most recent Catalog of Federal Domestic Assistance.

              RELATED COMMITTEE AND SUBCOMMITTEE HEARINGS

    Pursuant to clause 3(c)(6) of rule XIII, the following 
related hearing was used to develop or consider H.R. 4534:
           On February 14, 2024, the Subcommittee on 
        Health held a hearing on H.R. 4534. The title of the 
        hearing was ``Legislative Proposals to Support Patients 
        and Caregivers.'' The Subcommittee received testimony 
        from:
                   Andy Shih, PhD, Chief Science 
                Officer, Autism Speaks;
                   Corey Feist, JD, MBA, Co-Founder 
                and CEO, Dr. Lorna Breen Heroes' Foundation;
                   Joanne Pike, DrPH, President and 
                CEO, Alzheimer's Association;
                   Gordon Tomaselli, MD, Former 
                President, American Heart Association; Marilyn 
                and Stanley M. Katz Dean, Emeritus and 
                Professor of Medicine, Albert Einstein College 
                of Medicine; Adjunct Professor of Medicine, 
                Johns Hopkins University School of Medicine;
                   Michelle Whitten, President, 
                CEO, and Co-Founder, Global Down Syndrome 
                Foundation;
                   Randy Strozyk, President, 
                American Ambulance Association; and,
                   Christina Annunziata, MD, PhD, 
                Senior Vice President of Extramural Discovery 
                Science, American Cancer Society.

                        COMMITTEE COST ESTIMATE

    Pursuant to clause 3(d)(1) of rule XIII, the Committee 
adopts as its own the cost estimate prepared by the Director of 
the Congressional Budget Office pursuant to section 402 of the 
Congressional Budget Act of 1974. At the time this report was 
filed, the estimate was not available.

       EARMARK, LIMITED TAX BENEFITS, AND LIMITED TARIFF BENEFITS

    Pursuant to clause 9(e), 9(f), and 9(g) of rule XXI, the 
Committee finds that H.R. 4534 contains no earmarks, limited 
tax benefits, or limited tariff benefits.

                      ADVISORY COMMITTEE STATEMENT

    No advisory committees within the meaning of section 5(b) 
of the Federal Advisory Committee Act were created by this 
legislation.

                  APPLICABILITY TO LEGISLATIVE BRANCH

    The Committee finds that the legislation does not relate to 
the terms and conditions of employment or access to public 
services or accommodations within the meaning of section 
102(b)(3) of the Congressional Accountability Act.

             SECTION-BY-SECTION ANALYSIS OF THE LEGISLATION

Section 1. Short title

    Section 1 provides that the Act may be cited as the ``Women 
and Lung Cancer Research and Preventative Services Act of 
2024''.

Section 2. Interagency review to evaluate and identify opportunities 
        for the acceleration of research on lung cancer in women and 
        underserved populations, greater access to preventative 
        services, and strategic public awareness and education 
        campaigns

    Section 2 requires the Department of Health and Human 
Services (HHS) to conduct an interagency review on the status 
of, and identify research and education opportunities related 
to, women and certain underserved populations with lung cancer. 
The review would include assessments of current research and 
access to prevention services, the availability of research 
opportunities regarding prevention, detection, and treatment, 
and recommendations for national public education and screening 
strategies. This section also requires the HHS Secretary to 
submit a report to Congress detailing the results of the review 
within two years of enactment.

         CHANGES IN EXISTING LAW MADE BY THE BILL, AS REPORTED

    This legislation does not amend any existing Federal 
statute.

                                  [all]